| Literature DB >> 19500495 |
Abstract
Carotid disease may be evaluated by surrogate outcomes, such as intima-media thickness and carotid plaque features, and by clinical end points. Statins stop progression or may induce regression of intima-media thickness, and statins may also stop plaque growth or even induce reduction of plaque volume. Areas rich in lipids within plaques may be reduced in size and/or in number of inflammatory cells. Ultrasound reflectivity may be reduced by statin treatment, indicating less lipid/inflammatory content. Finally, statins appear to reduce the risk of all cardiovascular events (eg, stroke, myocardial infarction, need for revascularization) in patients with carotid stenosis. This review summarizes and discusses the existing data.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19500495 DOI: 10.1007/s11883-009-0047-1
Source DB: PubMed Journal: Curr Atheroscler Rep ISSN: 1523-3804 Impact factor: 5.113